EUVIMEDEUVIMED entdecken
Open Access

Frontal Cortex and Hippocampal γ-Secretase Activating Protein Levels in Prodromal Alzheimer Disease

Sylvia E Perez, Muhammad Nadeem, Michael H Malek-Ahmadi, Bin He, Elliott J Mufson

Neurodegenerative Diseases · 2017 · 17 (6) · 235-241

DOI: 10.1159/000477937 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurodegenerative Diseases, online erschienen am 26.07.2017. Verfasst von Sylvia E Perez und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurobiology, Barrow Neurological Institute, Phoenix, AZ, USA. Hauptthemen laut MEDLINE: Prodromal Symptoms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: β-Amyloid (Aβ) is the product of concerted cleavage of the amyloid precursor protein (APP) by β- and γ-secretases. However, the molecular mechanisms that regulate this process are not well understood. Recently, evidence was reported that γ-secretase activating protein (GSAP, 16 kDa), derived from a larger precursor protein (98 kDa), plays a role in Aβ metabolism through a mechanism involving its interaction with both γ-secretase and APP. However, a detailed evaluation of GSAP protein levels and their association with clinical and neuropathological variables are lacking during the clinical progression of Alzheimer disease (AD).

Methods

We quantified levels of the GSAP precursor (98 kDa) and its active form (16 kDa) in the frontal cortex and hippocampus, areas displaying extensive Aβ and neurofibrillary tangle (NFT) pathology, in subjects who came to autopsy with a premortem clinical diagnosis of noncognitive impairment, mild cognitive impairment, mild to moderate AD, and severe AD using Western blotting.

Results

Analysis found that 98-kDa GSAP levels were increased, while those of 16 kDa were reduced in the frontal cortex of severe-AD subjects. By contrast, GSAP levels remained stable in the hippocampus. Frontal cortex and hippocampal GSAP 98- and 16-kDa levels were not associated with Aβ, NFT, and neuropathological criteria across clinical groups. Interestingly, only neocortical 98-kDa GSAP values showed a significant correlation with the Mini-Mental State Examination and episodic memory scores.

Conclusions

These data demonstrate that GSAP proteins are differentially dysregulated in severe AD, but only the full-length form was associated with cognitive test scores in AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prodromal SymptomsAgedAged, 80 and overAlzheimer DiseaseCognitive DysfunctionFrontal LobeHippocampusHumansNeuropsychological TestsProteinsPsychiatric Status Rating Scales

Stichwörter der Autor:innen

Alzheimer diseaseFrontal cortexHippocampusMild cognitive impairmentWestern blotγ-Secretase activating protein

Substanzen

GSAP protein, humanProteins

Autor:innen und Institutionen

  • Department of Neurobiology, Barrow Neurological Institute, Phoenix, AZ, USA.

Förderung

  • NIA NIH HHS

Zitieren

APA

Perez, S. E., Nadeem, M., Malek-Ahmadi, M. H., He, B., & Mufson, E. J. (2017). Frontal Cortex and Hippocampal γ-Secretase Activating Protein Levels in Prodromal Alzheimer Disease. Neurodegenerative Diseases, 17(6), 235-241. https://doi.org/10.1159/000477937

Vancouver

Perez SE, Nadeem M, Malek-Ahmadi MH, He B, Mufson EJ. Frontal Cortex and Hippocampal γ-Secretase Activating Protein Levels in Prodromal Alzheimer Disease. Neurodegenerative Diseases. 2017;17(6):235-241. doi:10.1159/000477937

BibTeX
@article{Perez2017,
  author = {Perez, Sylvia E and Nadeem, Muhammad and Malek-Ahmadi, Michael H and He, Bin and Mufson, Elliott J},
  title = {Frontal Cortex and Hippocampal γ-Secretase Activating Protein Levels in Prodromal Alzheimer Disease},
  journal = {Neurodegenerative Diseases},
  year = {2017},
  volume = {17},
  number = {6},
  pages = {235--241},
  doi = {10.1159/000477937}
}
Kostenlos starten →